← All companies

LYCA

Lycia Therapeutics, Inc.

LYCA Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$26.40

-1.33 -4.80%

Key statistics

from XBRL data in SEC filings

Market cap ⓘ

—

Revenue (TTM) ⓘ

—

Net income (TTM) ⓘ

—

EPS (TTM) ⓘ

—

P/E ratio ⓘ

—

Dividend yield ⓘ

—

Free cash flow ⓘ

—

Cash ⓘ

—

Total assets ⓘ

—

Gross margin ⓘ

—

52-week range ⓘ

$22.19 – $36.49

Recent SEC filings

39 most recent

Annual, quarterly & current reports

8-K Amended charter or bylaws Oct 26, 2026

Other filings

SCHEDULE 13G Oct 30, 2026

S-8 Oct 23, 2026

424B4 Oct 23, 2026

EFFECT Oct 22, 2026

S-1MEF Oct 22, 2026

CERT Oct 22, 2026

8-A12B Oct 20, 2026

S-1/A Oct 20, 2026

S-1 DRS/A Oct 5, 2026

DRS/A Aug 27, 2026

DRS Jul 2, 2026

D Item 06b Jun 25, 2026

D Item 06b May 23, 2024

D Item 06b Sep 16, 2021

D Item 06b Mar 17, 2020